SEC 13F Intelligence

Managers / Q3 2024 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$169M
Q3 2024
Positions
90
Filings on Record
30
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Sectoral Asset Management Inc reported $169M in U.S.-listed holdings across 90 positions for Q3 2024.

Its largest position, LENZ, represents 13.7% of the portfolio.

Compared with Q2 2024, the fund opened 8 new positions and exited 15.

Portfolio Metrics

Turnover
+10.1%
vs prior filed quarter
Top-10 Concentration
+46.9%
share of reported value
Largest Position
+13.7%
Lenz Therapeutics
New / Exited
8 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.1%ADR: 6.6%Other: 4.3%ETP: 1.0%
  • Common Stock · 88.1% · $149M
  • ADR · 6.6% · $11M
  • Other · 4.3% · $7M
  • ETP · 1.0% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ISHARES TRUSTNEW+15.2K15.2K+$2M$2M
UNIQURE N.V.NEW+153.0K153.0K+$754,290$754,290
ENGENE HOLDINGS INCNEW+94.2K94.2K+$621,845$621,845
TARSTARSUS PHARMACEUTICANEW+11.3K11.3K+$371,657$371,657
SWTXUSDSPRINGWORKS THERAPEUNEW+10.0K10.0K+$320,720$320,720
NVONOVO-NORDISK ASNEW+2.2K2.2K+$261,954$261,954
GONGERON CORPNEW+46.0K46.0K+$208,840$208,840
J P MORGAN EXCHANGENEW+2.5K2.5K+$126,850$126,850

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LENZLENZ THERAPEUTICShistory →COM13.70%$23M977.2K
2CTNMCONTINEUM THERAhistory →CL A9.05%$15M800.9K
3LLYLILLY ELI & COhistory →COM5.75%$10M11.0K
4UNHUNITEDHEALTH GRP INChistory →COM4.53%$8M13.1K
5GILDGILEAD SCIENCES INChistory →COM3.02%$5M61.1K
6JNJJOHNSON & JOHNSONhistory →COM2.48%$4M25.9K
7MLYSMINERALYS THERAPEUTIhistory →COM2.36%$4M329.5K
8REGNREGENERON PHARMCTCLShistory →COM2.11%$4M3.4K
9PFEPFIZER INChistory →COM1.96%$3M114.7K
10TMOTHERMO FISHER SCIhistory →COM1.92%$3M5.3K
11ABBVABBVIE INChistory →COM1.84%$3M15.8K
12BSXBOSTON SCIENTIFIChistory →COM1.63%$3M33.0K
13MRKMERCK & CO INChistory →COM1.61%$3M24.0K
14SYKSTRYKER CORPhistory →COM1.59%$3M7.5K
15ALNYALNYLAM PHARMACUETCLhistory →COM1.57%$3M9.7K
16MEDTRONIC PLCSHS1.56%$3M29.4K
17BMRNBIOMARIN PHARMAC INChistory →COM1.53%$3M36.9K
18BMYBRISTOL MYERS SQUIBBhistory →COM1.53%$3M50.0K
19AZNNASTRAZENECAhistory →SP ADR1.46%$2M21.3K
20BOLDBOUNDLESS BIO INChistory →COM1.39%$2M678.6K
21AMGNAMGEN INChistory →COM1.35%$2M7.1K
22VRTXVERTEX PHARMAhistory →COM1.33%$2M4.8K
23ABTABBOTT LABShistory →COM1.31%$2M19.4K
24ARGXARGENX SEhistory →SP ADR1.28%$2M4.0K
25IQVIQVIA HOLDINGS INChistory →COM1.06%$2M7.6K
26ZLABZAI LAB LTDhistory →ADR1.04%$2M72.9K
27EWEDWARDS LIFESCIENCEhistory →COM1.01%$2M25.9K
28PCVXVAXCYTE INCCOM0.98%$2M14.5K
29CVSCVS HEALTH CORPCOM0.95%$2M25.5K
30BNTXBIONTECH SESP ADR0.92%$2M13.2K
31SRPTSAREPTA THERAPEUTICSCOM0.91%$2M12.3K
32ISHARES TRUST0-3 MNTH TREASRY0.90%$2M15.2K
33CYTKCYTOKINETICS INCCOM0.89%$2M28.6K
34AM6AMICUS THERAPEUTICSCOM0.89%$2M141.3K
35ISRGINTUITIVE SURGIC INCCOM0.89%$1M3.0K
36ZBHZIMMER BIOMET HLDSCOM0.86%$1M13.5K
37NBIXNEUROCRINE BIOSCIENCCOM0.85%$1M12.5K
38SPRYARS PHARMACEUTICALSCOM0.84%$1M98.6K
392655787DBLUEPRINT MEDICINESCOM0.82%$1M14.9K
40MLTXMOONLAKE IMMUNOTHERACLASS A ORD0.81%$1M27.3K
41DHRDANAHER CORPCOM0.78%$1M4.8K
42LEGNLEGEND BIOTECH CORPSP ADR0.78%$1M27.2K
43ICON PLCSHS0.78%$1M4.6K
44OPCHOPTION CARE HEALTHCOM0.74%$1M40.0K
45BIIBBIOGEN INCCOM0.69%$1M6.0K
46RCUSARCUS BIOSCIENCESCOM0.68%$1M75.5K
47ARVNARVINAS INCCOM0.67%$1M45.8K
48EVHEVOLENT HEALTH INCCL A0.65%$1M39.0K
49GPCRSTRUCTURE THERAPEUSP ADR0.63%$1M24.4K
50INARI MED INCCOM0.61%$1M25.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.